Sulindac sulfide and exisulind inhibit expression of the estrogen and progesterone receptors in human breast cancer cells

Clinical Cancer Research

Volumn 12, Issue 11 I, 2006, Pages 3478-3484

  Lim, Jin T E ^a   Joe, Andrew K ^a   Suzui, Masumi ^b   Shimizu, Masahito ^a   Masuda, Muneyuki ^c   Weinstein, I Bernard ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b UNIVERSITY OF THE RYUKYUS   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP DEPENDENT PROTEIN KINASE; CYCLIN D1; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; RETINOIC ACID RECEPTOR ALPHA; RETINOIC ACID RECEPTOR BETA; SULINDAC SULFIDE; SULINDAC SULFONE;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CULTURE; CONTROLLED STUDY; DOWN REGULATION; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; HORMONE ACTION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL ANALYSIS;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, REPORTER; HUMANS; PROMOTER REGIONS (GENETICS); RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETINOID X RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; STRUCTURE-ACTIVITY RELATIONSHIP; SULINDAC; TRANSCRIPTION, GENETIC; TRANSFECTION;

EID: 33745210520     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-05-2051     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics. CA Cancer J Clin 2006;56:106-30.
2. Sadan O, van Iddekinge B, Savage N, Robinson M, Zakut H. Ethnic variation in estrogen and progesterone receptor concentration in leiomyoma and normal myometrium. Gynecol Endocrinol 1988;2:275-82.
3. Savage N, Levin J, De Moor NG, Lange M. Cytosolic oestrogen receptor content of breast cancer tissue in blacks and whites. S Afr Med J 1981;59:623-4.
4. Verheul HA, Coelingh-Bennink HJ, Kenemans P, et al. Effects of estrogens and hormone replacement therapy on breast cancer risk and on efficacy of breast cancer therapies. Maturitas 2000;36:1-17.
5. Marsden J. Hormone-replacement therapy and breast cancer. Lancet Oncol 2002;3:303-11.
6. Lawrence JA, Dhringra K. Nuclear receptor superfamily. In: Kelloff GJ, Hawk ET, Sigman CC, editors. Cancer chemoprevention, vol. 1. Promising cancer chemoprevention agents. Totowa (NJ): Humana Press Inc.; 2004. p. 195-208.
7. Graslow JR. Optimizing the treatment of metastatic breast cancer. Breast Cancer Res Treat 2005;89: S9-15.
8. Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328: 1313-6.
9. Stoner GD, Budd GT, Ganapathi R, et al. Sulindac sulfone induced regression of rectal polyps in patients with familial adenomatous polyposis. Adv Exp Med Biol 1999;470:45-53.
10. Han EK-H, Arber N, Yamamoto H. Effects of sulindac and its metabolites on growth and apoptosis in human mammary epithelial and breast carcinoma cell lines. Breast Cancer Res Treat 1998;48:195-203.
11. Lim JT, Piazza GA, Han EK. Sulindac derivatives inhibit growth and induce apoptosis in human prostate cancer cell lines. Biochem Pharmacol 1999;58: 1097-107.
12. Lim JT, Piazza GA, Pamukcu R, Thompson WJ, Weinstein IB. Aptosyn® and related compounds inhibit expression and function of the androgen receptor in human prostate cancer cells. Clin Cancer Res 2003;9:4972-82.
13. Goluboff ET, Shabsigh A, Saidi JA. Exisulind (sulindac sulfone) suppresses growth of human prostate cancer in a nude mouse xenograft model by increasing apoptosis. Urology 1999;53:440-4.
14. Goluboff ET, Prager D, Rukstalis D. Safety and efficacy of exisulind in the treatment of recurrent prostate cancer following radical prostatectomy. J Urol 2001; 166:882-6.
15. Suzui M, Masuda M, Lim JT, Albanese C, Pestell RG, Weinstein IB. Growth inhibition of human hepatoma cells by acyclic retinoid is associated with induction of p21 (CIP1) and inhibition of expression of cyclin D1. Cancer Res 2002;62:3997-4006.
16. Russo J, Hasan Lareef M, Balogh G, Guo S, Russo IH. Estrogen and its metabolites are carcinogenic agents in human breast epithelial cells. J Steroid Biochem Mol Biol 2003;1:1-25.
17. Saunders PT, Millar MR, Williams K, et al. Expression of oestrogen receptor beta (ERbeta1) protein in human breast cancer biopsies. Br J Cancer 2002;86:250-6.
18. Palmieri C, Cheng GJ, Saji S, et al. Estrogen receptor beta in breast cancer. Endocr Relat Cancer 2002;9: 1-13.
19. Kastner P, Krust A, Turcotte B, et al. Two distinct estrogen-regulated promoters generate transcripts encoding the two functionally different human progesterone receptor forms A and B. EMBO J 1990;9: 1603-14.
20. Sartorius CA, Melville MY, Hovland AR, Tung L, Takimoto GS, Horwitz KB. A third transactivation function (AF3) of human progesterone receptors located in the unique N-terminal segment of the B-isoform. Mol Endocrinol 1994;8:147-60.
21. Mason BH, Holdaway IM, Mullins PR, Yee LH, Kay RG. Progesterone and estrogen receptors as prognostic variables in breast cancer. Cancer Res 1983;43: 2985-90.
22. Ariazi EA, Clark GM, Mertz JE. Estrogen-related receptor alpha and estrogen-related receptor gamma associate with unfavorable and favorable biomarkers, respectively, in human breast cancer. Cancer Res 2002;62:6510-8.
23. Gronemeyer H, Gustafsson JA, Laudet V. Principles for modulation of the nuclear receptor superfamily. Nat Rev Drug Discov 2004;11:950-64.
24. Thompson WJ, Piazza GA, Li H. Aptosyn™ induction of apoptosis involves guanosine 3′,5′-cyclic monophosphate phosphodiesterase inhibition, protein kinase G activation, and attenuated beta-catenin. Cancer Res 2000;60:3338-42.
25. Soh JW, Mao Y, Liu L, Thompson WJ, Pamukcu R, Weinstein IB. Protein kinase G activates the JNK1 pathway via phosphorylation of MEKK1. J Biol Chem 2001;276:16406-10.
26. Deguchi A, Xing SW, Shureiqi I, et al. Activation of protein kinase G (PKG) up-regulates expression of 15-lipoxygenease-1 in human colon cancer cells. Cancer Res 2005;65:8442-7.
27. Fitzgibbons PL, Page DL, Weaver D, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
28. Sommer S, Fuqua SA. Estrogen receptor and breast cancer. Semin Cancer Biol 2001;11:339-52.
29. Sneige N. Utility of cytologic specimens in the evaluation of prognostic and predictive factors of breast cancer: current issues and future directions. Diagn Cytopathol 2004;30:158-65.
30. Stonelake PS, Baker PG, Gillespie WM, et al. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer. Eur J Cancer 1994;30A: 5-11.
31. Gelbfish GA, Davidson AL, Kopel S, et al. Relationship of estrogen and progesterone receptors to prognosis in breast cancer. Ann Surg 1988;207: 75-9.